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Nitric oxide has a key role in vascular homeostasis. It plays a protective role by suppressing abnormal proliferation of
vascular smooth muscle following various pathological situations including atherosclerosis and restenosis after vascular
interventions such as balloon angioplasty, stent deployment and bypass grafting. It also has strong antiplatelet and anti-
thrombogenic properties. In this review, possible applications to daily vascular and endovascular surgery practice,
including systemic use of NO donors, enhancing endogenous production of NO by L-arginine and gene therapy, local
delivery strategies and coating stents and grafts with NO-delivering/enhancing chemicals are reviewed.
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Introduction central and peripheral nervous systems. nNOS regulates
norepinephrine release, and its expression increases fol-
Nitric oxide (NO) is the smallest known mammalian lowing physical and mechanical stress, nerve injury,8
ischaemia, hypoxia,9 changes in plasma osmolarity,10biological signalling molecule and plays an essential
role in human physiology.1] Here, the relationship and during pregnancy.11 Endothelial NOS (eNOS) is
found in venous, arterial and capillary endothelialbetween NO and intimal hyperplasia, and possible
implications for vascular surgery, are reviewed. cells,12 as well as myocytes13 and platelets.14 Haemo-
dynamic shear stress, chronic exercise, thrombocyte
growth factor- (TGF-) and chronic hypoxia increase
eNOS transcription.15–17 eNOS mediates endothelial cell
Biochemistry, Synthesis and Functions of Nitric proliferation and vasodilatation and inhibits vascular
Oxide smooth muscle proliferation, platelet adhesion/ag-
gregation, leukocyte and monocyte adhesion. UnlikeNitric oxide (NO) is a highly reactive free radical, these two isoforms that are often found at stable levelswhich has the potential to participate in a wide variety in their characteristic tissues, the inducible NOS (iNOS)of reactions to yield complex biological responses.1–3 is not found constitutively and its expression is inducedNO is an important regulatory determinant of vascular after immunoactivation of macrophages, monocytes,tissue homeostasis (Fig. 1) and acts through a variety and other immunocompetent cells.18–20 Although ex-of signalling elements, including the cGMP (cyclic ceptions exist, this induction generally reflects a patho-guanosine monophophate) and related protein kinase physiological cellular response to immunoactivation,19–21G (PKG) systems.4 PKG-independent pathways may and elicits vasoplegia, myocardial depression, cytotoxicalso be important.5 effects and apoptosis.22NO is derived enzymatically from the oxidation of NO is highly susceptible to oxidation by the super-L-arginine6 by nitric oxide synthase (NOS), which exits oxide anion, and the integrity and activity of NO de-in three isoforms: nNOS, iNOS and eNOS. Neuronal pends on adequate scavenging of this radical.23 AbsenceNOS (nNOS) is found mainly in nerve terminals7 in the of nitric oxide synthesis also leads to superoxide ac-
cumulation. In many vascular diseases, superoxide
anion levels increase, superoxide dismutase is over-∗ Please address all correspondence to: K. M. Vural, N. Tandogan
cad. 5/6 Kavaklidere 06540, Ankara, Turkey. whelmed, and the bioactivity of NO is thereby reduced.24
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Fig. 1. Complex interactions between NO and surrounding milieu in vascular homeostasis. Nitric oxide (NO) is synthesised during the
conversion of L-arginine to L-citrulline by Nitric Oxide Synthase (eNOS) in endothelial cells and counteracts with the effects of superoxide
radical produced under oxydative stress. Oxydative stimulus causes Nuclear factor B (NFB) to travel to the nucleus and activate gene
expression resulting in vascular cell adhesion molecule (VCAM-1) and monocyte chemotactic factor expressions. NO inhibits platelet
adhesion and aggregation by inhibition of calcium influx, suppressing cellular signaling cascades, phosphorilation of thromboxane-A2
receptors, decreasing surface glycoprotein receptor expression and inhibition of eicosanoid mediator formation. NO also have an inhibitory
effect on leukocyte and monocyte adhesion/migration and, therefore, may prevent the transformation of tissue macrophages into foam
cells. NO causes relaxation of vascular smooth muscle cells via the activation of guanylyl cyclase (GC) and increased cyclic guanosine
monophosphate (cGMP) formation. A number of mitogenic factors for endothelial cells including vascular endothelial growth factor
(VEGF), Interleukin-1 and Substance-P requires NO production to exert their effects on endothelial cell growth during vascular healing.
Role of Nitric Oxide in Vascular Homeostasis endothelial cells, and stimulates endothelial cell
growth, especially during angiogenesis and wound
The primary role of NO as a physiological regulator healing. Other major effects are to decrease endothelin
release and to regulate vasodilatory prostaglandinsderives from its constitutive production driven by the
shear forces on the endothelium.25 Following diffusion (prostacyclin). NO also plays an important role in the
maintenance of endothelial barrier function.28 NO hasto smooth muscle cells, NO stimulates a variety of
mechanisms, which causes relaxation by decreasing an inhibitory effect on platelet activation4 and may also
affect bleeding times by interfering with the fibrinolyticintracellular free calcium and also the sensitivity of
contractile proteins to calcium. In addition to this system. It should be noted that as diminished NO
production leads to an increase in the platelet ag-paracrine control mechanism, NO participates in re-
gulation of both sympathetic and parasympathetic gregatory response, excessive NO bioactivity can lead
to haemorrhagic states, as happens in sepsis andcontrol mechanisms. Many humoral substances, in-
cluding acetylcholine and bradykinin, stimulate spe- uraemia.29
cific receptors on the endothelial surface to mediate an
increase in endothelial cell calcium and NOS. Although
NO is the primary vasodilator released from endo-
thelial cells, it interplays with other vasoactive sub- Cytotoxicity, Apoptosis, and Nitric Oxide
stances, including prostacycline, in regulating vascular
tone.26 High levels of NO assist in non-specific immune de-
fence through its potent cytotoxicity against invadingVascular smooth muscle is the prototypical target
tissue for NO, and principal effects are relaxation, microorganisms, as well as tumour cells.30,31 However,
this is also destructive for the surrounding tissue. Bothgrowth inhibition and the promotion of apoptosis
(programmed cell death).27 Endothelial cells are the pro-32 and anti-apoptotic33 effects of NO have been
demonstrated. Under physiologic conditions lowprimary source of NO in the vascular system. NO
release occurs in response to acetylcholine or shear levels of NO inhibits apoptosis of immune-competent
cells and thereby supports immune defence, whereasstress. In contrast to its effects on vascular smooth
muscle cell, NO has an anti-apoptotic effect in vascular chronic high levels may induce cell death. NO has an
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anti-apoptotic effect on endothelial cells which leads formation.38 Endothelial injury promotes its pro-
coagulant, rather than anticoagulant, properties andto protection of the endothelium and, a pro-apoptotic
effect on the smooth muscle cells that reduces neo- leads to the expression of vasoactive molecules, cyto-
kines and growth factors.39intimal proliferation, assists in remodelling but pro-
motes atherosclerotic plaque destabilisation. Vascular Besides thrombogenity, disruption of the normal
protective endothelial barrier results in a series ofendothelial growth factor (VEGF) is synthesised by
smooth muscle cells and is a mitogen for endothelial responses that may lead to restenosis. Exposure of
subendothelial matrix elements results in platelet ad-cells. Arterial injury enhances VEGF gene expression
and VEGF increases NO production in endothelial hesion and activation with the release of chemotactic
and mitogenic factors. Adhesion and migration ofcells. Here, NO blocks apoptosis and enhances the
mitogenic effects of VEGF, interleukin-1 (IL-1) and leukocytes releases additional growth factors, leading
to migration and proliferation of vascular smoothsubstance-P during endothelial wound healing and
angiogenesis. NO released by regenerating endothelial muscle cells and myofibroblasts with formation of a
neo-intima. NO can modulate this response to acutecells has a negative feedback effect on VEGF ex-
pression.34 vascular injury by inhibiting several key components
in the process including platelet adhesion and ag-
gregation, leukocyte adhesion, and smooth muscle cell
proliferation.
Cellular Proliferation, Vascular Injury Healing,
Intimal Hyperplasia
The role of the adventitia in vascular remodelling
Endovascular stents
The adventitia plays an important role in normal
vascular function and in diseases such as athero- Endovascular stents were developed to overcome
two major limitations of balloon angioplasty: Acutesclerosis, hypertension, and restenosis.35 The major cell
type within the adventitia is the fibroblast, which periprocedural vessel closure often related to dissec-
tion and intimal tears, which complicates 2–3% ofexpresses iNOS upon inflammatory stimulation. There
are many reports indicating that mast cells, also present attempts,40 and chronic restenosis, which limits long-
term patency in 20–50% of patients.41 Because of theirin the adventitia, regulate leukocyte-endothelial cell
relations via NO.36 Mast cell membrane stabilising ability to seal intimal tears, stents may deal with
threatened or abrupt vessel closure.42 However,agents such as ketotifen and cromolyn may promote
vascular homeostasis, by increasing iNOS expression metallic stents are also very thrombogenic. In addition,
by applying a continuous pressure on the arterial wall,and tissue cGMP levels, while reducing intercellular
adhesion molecule-1 (ICAM-1) expression in the set- further vascular injury may ensue and aggravate the
restenotic process.ting of lung ischaemia and reperfusion.20 An in vitro
study on human saphenous vein graft segments dem-
onstrated that mast cell membrane stabilisation res-
ulted in reduced vascular cell adhesion molecule
(VCAM-1) and increased iNOS expression.37
Synthetic vascular grafts
Synthetic material, being foreign and devoid of endo-
thelial cells also represents a thrombogenic surface.43The role of the endothelium and vascular smooth muscle
in vascular remodeling This attracts platelets and leukocytes, leading to throm-
bosis and intimal hyperplasia. This response is not a
Bypass surgery, angioplasty, stent deployment, and major problem with large-diameter grafts (8–20 mm
in diameter) but is significant for small-diameter graftsendarterectomy are all complicated by aberrant heal-
ing characterised by excessive proliferation and mi- between 2–6 mm in diameter. Over time, they develop
an endothelial lining, which provides reasonable pro-gration of vascular smooth muscle cells. The main
problem is the lack of function of the normal protective tection against thrombosis. However, vascular grafts
are not effective at diameters less than 3 mm in dia-endothelial layer that lines arterial walls and secretes
a variety of protective substances, including NO that meter because they become occluded with intimal
hyperplasia and thrombotic material.44inhibit platelet adhesion, aggregation, and thrombus
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Systemic Use of NO Donors for Preventing flow.50 A single intravenous dose of L-arginine (30 g
over 60 min) results in 42% increase in femoral arteryThrombosis and Restenosis after Angioplasty
blood flow. Furthermore, daily intravenous ad-
ministration of arginine for two weeks improvesNO donors
walking distance in patients with intermittent claudi-
cation.51 Daily infusions of L-arginine (12.6 g) for 7Systemic delivery of organic NO donor compounds
such as molsidomine inhibits platelet adhesion and days increased calf blood flow and transcutaneous
oxygen saturation, improved walking distance,smooth muscle cell proliferation following balloon-
induced carotid artery injury in pigs.45 In this model, shortened the time period to recovery from pain and
reduced platelet aggregation and clot lysis time.51,52platelet thrombus formation was reduced by systemic
administration of 3-morphplinosydnonimine (SIN-1), The enhancement in blood flow is extended to the
microvascular circulation as well. Thirty grams ofa spontaneous NO donor and molsidomine meta-
bolite.46 Administration of this agent also increased intravenous L-arginine was able to enhance calf muscle
blood flow from 1.7±0.1 to 2.2±0.2 mL/min/100 gbleeding time and platelet cGMP. The ACCORD Study
suggested that administration of NO donors lin- at 80 min following infusion.53 Preliminary evidence
suggests that administration of L-arginine-enrichedsidomine and molsidomine to patients undergoing
coronary angioplasty lead to a modest improvement food can increase walking distance and quality of life
in patients with peripheral arterial disease. Consistentin the immediate angiographic outcome, with a greater
minimal luminal diameter.47 At the 6th-month an- with observations in other patient populations, daily
infusions of L-arginine (60 mmol) reduced ADP-in-giographic follow-up, this modest improvement is
sustained although there is no protection against late duced platelet aggregation and shortened euglobin
clot lysis time in patients with peripheral arterial dis-luminal loss.47 Similarly, local delivery of a stable
protein S-nitrosothiol reduces platelet deposition and ease who are known to have hyperaggregable plate-
lets.52,54,55 These antithrombotic effects of L-arginineinhibits neointimal proliferation after vascular injury.48
Nitrosation of low-molecular-weight thiols or cysteinyl may add to its vasodilatory effect to enhance overall
walking ability and quality of life in this population.side chains of proteins occurs in the aqueous phase to
yield RSNOs (s-nitrosothiol). RSNOs are formed in In addition, the improvement in endothelial function
with L-arginine supplementation is associated withvivo by the reaction of bioavailable NO with sulfhydryl
groups. RSNOs serve as a circulating reservoir of stable decreased neointima formation.56
NO and allow NO to function in a paracrine fashion.
These compounds further protect NO from reactive
Gene therapy approachesoxygen species. RSNOs contribute significantly to the
NO production could be restored using gene transferpharmacological and physiological responses of the
techniques to deliver the eNOS gene to the site ofcardiovascular system, including maintenance of vas-
vascular injury. This might lead to inhibition of neo-cular tone, the response of the vessel wall to injury
intima formation and prevent platelet aggregation.and inhibition of platelet aggregation. Attenuation of
Transfection with eNOS improves vascular NO pro-intimal and medial proliferation by local ad-
duction with restoration of endothelium-dependentministration of RSNOs following balloon angioplasty
relaxation and leads to a 70% reduction in neointimasuggests a therapeutic role for these agents in pre-
formation 14 days after balloon-induced injury in ratventing restenosis. In a rabbit model of bilateral fem-
carotid arteries.57 In a balloon injury model, it wasoral artery injury, treatment with a polynitrosated S-
demonstrated that retroviral-mediated overexpressionnitroso-albumin demonstrated a significant decrease
of eNOS in smooth muscle cells can limit neointimalin platelet aggregation and intimal hyperplasia.49 In
formation by inhibiting cell proliferation and in-summary, following arterial injury, augmenting NO
creasing the production of NO.58 In addition, iNOSproduction or providing exogenous NO reduces in-
gene transfer using an adhesive vector has been showntimal hyperplasia in animal models. However, whether
to inhibit neointimal hyperplasia following balloonthis is a benefit in human subjects remains unknown.
injury in rats and pigs. This inhibition of neointimal
proliferation by NOS gene transfer is, in part, the
result of antiproliferative action on vascular smoothEnhancing endogenous NO production
muscle cells.59 eNOS expression inhibits DNA syn-
thesis and reduces vascular smooth muscle cell pro-L-arginine
liferation following arterial injury, and subsequentIn patients with severe vascular disease, intravenous
L-arginine has been shown to improve limb blood enhancement in NO production is associated with an
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inhibition of neointimal formation with a reduction in Coating blood-contact surfaces strategies
the intima-to-media ratio.60
Insoluble NO-releasing polymers can be used to coat
prosthetic vascular grafts. Diazeniumdiolates can be
incorporated into polymeric matrices of different struc-
Local Delivery of Chemical Agents for tural types. Prodrugs can be designed to protect the
Augmentation of Tissue Nitric Oxide Levels terminal oxygen; and binding of the prodrug facilitates
its concentration in the target tissue or cell. This is
Local infusion strategies achieved by cross-linking polyethylenimine onto com-
mercial polytetrafluoroethylene grafts, then exposing
The demonstrated efficacy of diazeniumdiolates as them to NO to introduce the diazeniumdiolate func-
agents for inhibiting platelet adhesion in vivo lead to tional group. Inserting of these grafts into the baboon
the hypothesis that their local application at the site arteriovenous shunt system led to dramatic reductions
of vascular graft placement would reduce the risk of in platelet attachment over a 1-hour observation
thrombosis, even in the absence of systemic anti- period. Grafts emitting NO at the rate of 1–2 nmol/
coagulation.61 With the local administration of PROLI/ min/mg remained patent, whereas control grafts
NO (proline is the NO-carrying molecule here) via blocked with thrombus within an hour.65,66 An alternate
the boundary layer, dogs undergoing femoral artery approach is to embed microspheres of the same cross-
endarterectomy immediately downstream displayed linked polyethylenimine diazeniumdiolate into the
significantly less smooth muscle cell proliferation at pores of the polytetrafluoroethylene fabric.67
the injury site 7 days after the surgery. PROLI/NO
infused at an initial rate of 7 nmol/min reduced pro-
liferation by 43% at the distal anastomosis and by 68%
Coating endovascular stentsat the site of endarterectomy relative to the contra-
lateral vessels infused with the carrier molecule proline
A stent offers a unique opportunity for local druginstead.62
delivery, since it will be placed in very close contact
with the acutely injured arterial wall and interfaces
with the blood. Polymer coating of the Wall⊂ stent
(Schneider, Minneapolis, MN, U.S.A.) with cross-Local embedding strategies
linked methane (Biogold) decreases early thrombosis
of stents placed in pigs by 38% compared with un-A better approach might be to incorporate di-
azeniumdiolates into the graft itself, thereby elim- coated stents. However, this polymer coating did not
reduce neointimal hyperplasia significantly.68 Anotherinating the need for the infusion. The anionic
complexes discussed above decompose spontaneously approach is to coat the stent with genetically en-
gineered endothelial cells. Using retroviral-mediatedat physiological pH, some of them rapidly. Delivering
NO to a targeted area before decomposition, and gene transfer, the gene for human tissue-type plasm-
inogen activator (t-PA) was inserted into culturedwithout interfering with other NO-dependent func-
tions, remains a challenge. Periadventital application sheep endothelial cells.69 These endothelial cells release
PGI2, NO, and high concentrations of t-PA, but doof diazeniumdiolates may be a possibility.63 In a rabbit
model of atheroma induction by placing a collar not stick to bare metal stents. A substrate such as
fibronectin is necessary before cells will seed.69 How-around the carotid artery; neointima formation after 14
days was reduced by 74% when the collars contained ever, fibronectin ‘‘glue’’ is itself thrombogenic69 and if
some seeded endothelial cells are released from theSPER/NO (spermine is the NO-carrying molecule)
at an initial concentration of 1 mg/mL relative to stent, the remained fibronectin-coated surface will be
more thrombogenic than the bare stent itself. In vivocontralateral control arteries whose collars contained
carrier molecular spermine at similar concentrations.63 studies has been disappointing, possibly for this
reason.69 In addition, maintaining the viability ofIn experiments with hypercholesterolaemic rabbits,
jugular vein implants in the carotid artery were packed seeded endothelial cells is difficult. A different ap-
proach employs a fibrin film soaked in heparin thatperivascularly with a biodegradable polymer con-
taining SPER/NO. Intimal thickening was reduced by is then used as a circumferential coating on a stent.70
These coated stents provide with less thrombotic oc-more than 40% in treated vein grafts relative to controls
at 28 days after the implantation in arterial cir- clusion, less neointimal hyperplasia and greater pat-
ency.70 Preliminary studies with a heparin-coatedculation.64
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Benestent in patients also showed that the heparin- grafts to deliver therapeutic amounts of NO (i.e.
10 nmol NO /mg with a half-life of 51 h) for thecoated stent significantly decreased early thrombotic
closure compared to an uncoated stent.71 There was, prevention of thrombosis and restenosis.67 In-
corporated [N(O)NO] group into polymeric matriceshowever, no significant reduction in restenosis in this
study. can be used for altering the time course of NO release.65
The cross-linked poly-ethylenimine that has been ex-
posed to NO inhibited the in vitro proliferation of rat
Coating of synthetic grafts aorta smooth muscle cells when added as a powder
to a culture medium. It also showed potent antiplatelet
Artificial surfaces in contact with blood quickly activity when coated on a normally thrombogenic
develop a coating of adsorbed plasma protein that vascular graft situated in an intravenous shunt in a
governs subsequent interaction with blood cells. This baboon’s circulatory system.65
initial protein adsorption occurs within seconds, before pS-NO-BSA might also be placed on stents and used
the blood platelets and other cellular components reach for local delivery of NO. Palmaz-Schatz stents coated
the arterial surface.72 Much research has focused on the with pS-NO-BSA were compared to bare stents de-
role of the most prevalent plasma proteins. Albumin is ployed in anesthetised pigs in six pairs of carotid
the most abundant protein in serum, and albumin arteries. pS-NO-BSA coating significantly retarded
coating has been used to make synthetic surfaces early platelet deposition.80 The pS-NO-BSA-coated
more thromboresistant.73 By contrast, polymer surfaces stents had a 40% reduction in neointimal area com-
coated with fibrinogen, another abundant protein in pared to bare stents.80 There was also a statistically
serum, promotes platelet activation and presents a significant reduction in average neointimal thickness.80
very thrombogenic surface.74 Thus, the initial protein Thus, it appears that a pS-NO-BSA-coated stent offers
layer adsorbed to the polymer surface is very im- promise for further studies to inhibit early thrombosis
portant in determining the thrombogenicity of that and late restenosis. One way to test the coating of
surface.72 Albumin has been used for coating vascular damaged arterial walls is the direct application of
grafts to ‘‘passivate’’ surfaces in contact with blood pS-NO-BSA to the angioplastied femoral arteries of
and, thus, minimise surface-induced platelet ac- anaesthetised rabbits. After angioplasty of each fem-
tivation.75 Serum albumin can be modified to bear a oral artery, one is exposed and coated with BSA,
covalently linked S-NO functional group that mani- prepared for nitrosation (pS-BSA) but without NO
fests nitrovasodilation and platelet inhibitory prop- incorporation. The other femoral artery is coated with
erties.76 In addition, bovine serum albumin (BSA) has chemically modified BSA (pS-NO-BSA) that does con-
been chemically modified so that the molar ratio of S- tain NO. The rabbits were then allowed to recover
NO to albumin is greater than 1:1.59 This modification for 14 days. The artery receiving pS-NO-BSA had a
produces a polynitrosated albumin (pS-NO-BSA), significantly larger lumen 0.86×105 M2 compared to
which can be applied locally to foreign surfaces or to the control 0.31×105 M2 (p=0.01) and the treated
severely damaged arterial walls to make them less arteries had 81% less neointimal area (p=0.02).59 In
thrombogenic.59,77,78 Among the most stable NO do- these studies, the pS-NO-BSA also significantly in-
nating compounds are the S-nitroso-thiols, such as S- hibited radio labeled platelet binding to the damaged
nitrosated albumin.76 S-nitroso-thiols serve as carriers arterial surface compared to control surfaces. Finally,
in the mechanism of action of NO by stabilising the when the arteries treated with pS-NO-BSA were ex-
labile NO.76 In the dog, nitrosated albumin has been posed to platelets for 1 min, they increased platelet
shown to inhibit in vivo platelet aggregation when cGMP levels more than fourfold compared to control,
given systemically79 or locally.78 It would seem reason- untreated arteries. Thus, the pS-NO-BSA reacted in a
able that local delivery of an NO-like species (pS-NO- similar fashion when the NO donor was applied to
BSA) to restore or replace the relative deficiency of implanted stents and when it was applied directly to
NO observed dysfunctional, acutely damaged endo- damaged rabbit arteries.
thelium could modulate the effect of vascular injury
and potentially reduce platelet aggregation and reduce
intimal proliferation after angioplasty or stent de-
ployment. This has been examined in several recent Conclusion
studies, where platelets were exposed to collagen or
other coated surfaces. Nitric oxide is an important regulatory determinant
of vascular tissue homeostasis. It may play a protectiveNO-releasing cross-linked polyetheleneimine micro-
spheres can be incorporated into the pores of vascular role by inhibiting abnormal proliferation of vascular
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